Radiation safety issues related to radiolabeled antibodies. [Contains glossary]

Technical Report · Fri Mar 01 00:00:00 EST 1991

OSTI ID:5941899

Barber, D E; Baum, J W; Meinhold, C B ^[1]

---

1. Brookhaven National Lab., Upton, NY (USA)

Techniques related to the use of radiolabeled antibodies in humans are reviewed and evaluated in this report. It is intended as an informational resource for the US Nuclear Regulatory Commission (NRC) and NRC licensees. Descriptions of techniques and health and safety issues are provided. Principal methods for labeling antibodies are summarized to help identify related radiation safety problems in the preparation of dosages for administration to patients. The descriptions are derived from an extensive literature review and consultations with experts in the field. A glossary of terms and acronyms is also included. An assessment was made of the extent of the involvement of organizations (other than the NRC) with safety issues related to radiolabeled antibodies, in order to identify regulatory issues which require attention. Federal regulations and guides were also reviewed for their relevance. A few (but significant) differences between the use of common radiopharmaceuticals and radiolabeled antibodies were observed. The clearance rate of whole, radiolabeled immunoglobulin is somewhat slower than common radiopharmaceuticals, and new methods of administration are being used. New nuclides are being used or considered (e.g., Re-186 and At-211) for labeling antibodies. Some of these nuclides present new dosimetry, instrument calibration, and patient management problems. Subjects related to radiation safety that require additional research are identified. 149 refs., 3 figs., 20 tabs.

• Research Organization: Nuclear Regulatory Commission, Washington, DC (USA). Div. of Regulatory Applications; Brookhaven National Lab., Upton, NY (USA)
• Sponsoring Organization: USNRC; Nuclear Regulatory Commission, Washington, DC (USA)
• DOE Contract Number: AC02-76CH00016
• OSTI ID: 5941899
• Report Number(s): NUREG/CR-4444; BNL-NUREG-52275; ON: TI91010005
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
LABELLING
ASTATINE 211
TISSUE DISTRIBUTION
INDIUM 111
IODINE 131
NUCLEAR MEDICINE
SAFETY STANDARDS
RADIATION PROTECTION
RHENIUM 186
TECHNETIUM 99
YTTRIUM 90
CLEARANCE
DOSE RATES
IMAGES
NEOPLASMS
RADIATION DOSES
RADIOPHARMACEUTICALS
RADIOTHERAPY
REGULATIONS
US NRC
ALPHA DECAY RADIOISOTOPES
ASTATINE ISOTOPES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
DAYS LIVING RADIOISOTOPES
DISEASES
DISTRIBUTION
DOSES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
HEAVY NUCLEI
HOURS LIVING RADIOISOTOPES
INDIUM ISOTOPES
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
MEDICINE
MINUTES LIVING RADIOISOTOPES
NATIONAL ORGANIZATIONS
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
RADIOISOTOPES
RADIOLOGY
RHENIUM ISOTOPES
STANDARDS
TECHNETIUM ISOTOPES
THERAPY
US ORGANIZATIONS
YEARS LIVING RADIOISOTOPES
YTTRIUM ISOTOPES
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)
550601 - Medicine- Unsealed Radionuclides in Diagnostics